Nrc Health (NRC) · Oct 27, 2026 · Earnings

NRC Health earnings grow 11%, but margins still lag

In line — Revenue $38.4M, adjusted EPS $0.21; no reliable published consensus located

NRC Health’s third-quarter earnings show 11% revenue growth and rising recurring contracts, but weaker year-to-date margins temper the recovery.

NRC Health is rebuilding after earlier sales, retention, product-innovation, and management-transition problems; the current strategy is to turn a growing subscription contract base with large healthcare systems into sustained revenue and operating leverage. Its TRCV had already climbed to record levels by early 2026, so stronger revenue was expected directionally rather than coming out of nowhere.

Revenue conversion is working. Third-quarter revenue rose 11% year over year to $38.4 million, while TRCV increased 9% to $154.1 million, supporting the thesis that the contracted-revenue recovery is beginning to flow through the income statement. 〔0〕

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
Revenue$38.4M$34.6M$108.6M$102.2M
GAAP diluted EPS$0.21$0.18$0.20$0.43
Adjusted diluted EPS$0.21$0.23$0.73$0.77
Adjusted EBITDA$10.9M$10.9M$29.7M$31.5M
Adjusted EBITDA margin28%31%27%31%
Free cash flow$7.0M$10.2M$12.4M$9.7M

The quarter improved, but the broader earnings recovery is incomplete. GAAP EPS increased year over year, yet adjusted EPS fell from $0.23 to $0.21 and adjusted EBITDA margin contracted from 31% to 28% in the quarter. For the first nine months, adjusted EBITDA declined 6% and the margin fell four percentage points, showing that revenue growth has not yet translated into sustained operating leverage. (Adjusted EBITDA reconciliation) 〔1〕

Cash generation is better year to date, but balance-sheet flexibility is limited. Nine-month free cash flow rose to $12.4 million from $9.7 million because capital spending fell sharply, but operating cash flow declined to $16.6 million from $19.3 million. The company also ended September with only $3.6 million of cash against roughly $102.9 million of notes payable, while shareholders’ equity was negative $9.1 million. (Cash Flow statement; Balance Sheet)

The customer story is validating, but not yet fully monetized. The company says a large customer went live on schedule and several long-standing customers renewed under multi-year agreements, which supports retention and future revenue visibility. 〔2〕 That direction was already known from prior updates, making this quarter more confirmation than a new demand shock.

Bottom line: NRC Health is successfully converting a stronger recurring-contract base into double-digit revenue growth, but profitability remains behind the recovery narrative. The filing matters as confirmation of progress, not as proof that operating leverage has fully arrived.

What to watch next

Q4 results, early February 2027

Original filing on SEC EDGAR

More Nrc Health news

NRC Health earnings grow 11%, but margins still lag | NRC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.